Live Broadcast on Metastatic Colorectal Cancer

Highlights From prIME Masterclass in Colorectal Cancer

Not a member of My prIME? Join now for instant access.

This meeting is only intended for physicians from the Asian Pacific region.

Meeting Overview

Hear from the experts during this live broadcast specifically designed to discuss highlights from prIME Masterclass in Colorectal Cancer. You will have the opportunity to interact with leading national and international multidisciplinary experts and gain valuable insight into the most up-to-date management concepts and emerging treatment strategies for patients with metastatic colorectal cancer (mCRC).

Date and Location

Saturday, 19 May 2018
17.00 – 18.00 Japan Standard Time
Tokyo, Japan



Saturday, 19 May 2018
17.00 – 18.00



Tokyo, Japan



  • Can mCRC be cured?
  • How should we personalize front-line therapy in mCRC?
  • The art of the continuum of care approach in mCRC and treatment sequencing beyond progression
  • mCRC in the coming years: What can we expect?
  • prIME Points™

Participants can send questions during the live broadcast.

  • René Adam, MD, PhDHepato Biliary Centre at Paul Brousse Hospital
    Villejuif, France
  • Scott Kopetz, MD, PhD, FACPUniversity of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Kun-Huei Yeh, MD, PhDNational Taiwan University Hospital
    National Taiwan University Cancer Center
    Taipei, Taiwan
  • Takayuki Yoshino, MD, PhDNational Cancer Center Hospital East
    Chiba, Japan

This educational activity is specifically designed for medical oncologists, gastroenterologists, surgical and radiation oncologists, and other healthcare professionals from the Asian Pacific region involved in the management of CRC.

After successful completion of this educational activity, participants should be able to:

  • Explain state-of-the-art management of early and metastatic CRC, and evaluate current and emerging biomarkers to guide personalized therapy
  • Identify multidisciplinary treatment approaches that may lead to optimal treatment outcomes for patients with liver-only metastases
  • Select optimal front-line treatment for mCRC and assess sequencing strategies beyond disease progression
  • Evaluate treatment options for metastatic BRAF-mutant mCRC
  • Describe emerging agents in mCRC, including immunotherapy-based combinations

This educational activity is supported by a grant from Merck KGaA, Darmstadt, Germany.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.


This activity is provided by prIME Oncology.


Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.